Dive Brief:

潜水简介：

Viatris is selling off three business units for more than $3 billion, the company said Sunday, seeking to reduce its debt as it works toward a plan to improve revenue growth, add new product lines and buy back shares.

该公司周日表示，Viatris以超过30亿美元的价格出售三家业务部门，试图减少债务，因为它致力于改善收入增长，增加新产品系列和购买股票。

In separate deals, Viatris will divest its consumer health, women’s health and active pharmaceutical ingredients businesses, although it will retain rights to some of its over-the-counter products. Added to a selloff of its biosimilars unit to Biocon in 2022, the company will raise $5.2 billion in total net proceeds..

在单独的交易中，Viatris将剥离其消费者健康，女性健康和活性药物成分业务，尽管它将保留部分非处方产品的权利。2022年，除了向Biocon出售生物仿制药部门外，该公司将筹集52亿美元的净收益总额。。

Formed by the merger of generics company Mylan and Pfizer subsidiary Upjohn, Viatris has struggled with debt that Mylan accrued during its acquisitive phase as well as broader market pressure on generic drug pricing. Notably, Sunday’s selloff involves an over-the-counter and generics business that Mylan gained when it bought Swedish drugmaker Meda for $7.2 billion in 2016..

通过仿制药公司Mylan和辉瑞子公司Upjohn的合并成立，Viatris一直在努力解决Mylan在收购阶段积累的债务以及更广泛的仿制药定价市场压力。值得注意的是，周日的selloff涉及Mylan在2016年以72亿美元购买瑞典药剂师Meda时获得的非处方药和仿制药业务。。

Dive Insight:

潜水洞察力：

Viatris aimed to bring its debt load down to three times earnings before accounting for taxes and interest by the first half of 2024, from 3.6 times earnings at the end of 2019. Company executives claim these transactions will get them there.

Viatris的目标是在2024年上半年之前将债务负荷降至收入的三倍，从2019年底的3.6倍收入中计算税收和利息。公司高管声称这些交易将把它们带到那里。

The first deal has Cooper Consumer Health spending $2.2 billion to take over Viatris’ consumer health business, which includes manufacturing sites in France and Italy and a research and development facility in Italy. Viatris will retain rights to erectile dysfunction pill Viagra in China, allergy spray Dymista in Europe and other select brands in some markets..

第一项协议由库珀消费者健康支出22亿美元接管Viatris的消费者健康业务，其中包括法国和意大利的制造基地以及意大利的研发机构。Viatris将保留中国勃起功能障碍药丸Viagra，欧洲过敏喷雾剂Dymista和某些市场其他精选品牌的权利。。

The women’s health unit is being bought by Spanish drugmaker Insud Pharma, which will gain two factories in India. Viatris is selling its India-based API business to Iquest Enterprises, a deal that will involve six manufacturing sites, an R&D facility and third-party sales.

女性健康部门正在被西班牙药剂师Insud Pharma购买，该公司将在印度获得两家工厂。Viatris正在将其基于印度的API业务销售给Iquest企业，该协议将涉及六个制造站点，一个研发设施和第三方销售。

In a separate transaction, meanwhile, women’s health specialist Theramex will buy the brands Duphaston and Femoston.

与此同时，在另一项交易中，女性健康专家Theramex将购买品牌Duphaston和Femoston。

Viatris listed the combined proceeds from the API and women’s health businesses at $1.2 billion.

Viatris将API和女性健康业务的综合收益列为12亿美元。

The company also divested Upjohn commercialization rights in countries where Viatris “had no established infrastructure.”

该公司还在Viatris“没有建立基础设施”的国家剥夺了Upjohn商业化权利

Viagra, Dymista and other retained products are valued at $1.6 billion, which executives said explained why it didn’t achieve the $5 billion in divestitures it initially planned. “We see further opportunities for these products within Viatris,” CEO Scott Smith said in a statement.

Viagra，Dymista和其他保留产品的价值为16亿美元，高管们表示，为什么它没有实现最初计划的50亿美元剥离。首席执行官斯科特·史密斯（Scott Smith）在一份声明中说：“我们在Viatris内部看到了这些产品的更多机会。

Shares in the company rose 3% in morning trading, changing hands at a little over $10 apiece.

该公司股票在早上交易中上涨了3%，每次换手略超过10美元。